AU2001271782A1 - Use of substituted insole compounds for treating excessive intraocular pressure - Google Patents
Use of substituted insole compounds for treating excessive intraocular pressureInfo
- Publication number
- AU2001271782A1 AU2001271782A1 AU2001271782A AU7178201A AU2001271782A1 AU 2001271782 A1 AU2001271782 A1 AU 2001271782A1 AU 2001271782 A AU2001271782 A AU 2001271782A AU 7178201 A AU7178201 A AU 7178201A AU 2001271782 A1 AU2001271782 A1 AU 2001271782A1
- Authority
- AU
- Australia
- Prior art keywords
- insole
- substituted
- compounds
- intraocular pressure
- treating excessive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 230000004410 intraocular pressure Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21618900P | 2000-07-06 | 2000-07-06 | |
| US60/216,189 | 2000-07-06 | ||
| PCT/US2001/021082 WO2002003990A2 (en) | 2000-07-06 | 2001-06-29 | Use of substituted insole compounds for treating excessive intraocular pressure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2001271782A1 true AU2001271782A1 (en) | 2002-01-21 |
Family
ID=22806079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001271782A Abandoned AU2001271782A1 (en) | 2000-07-06 | 2001-06-29 | Use of substituted insole compounds for treating excessive intraocular pressure |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US6509332B2 (en) |
| AU (1) | AU2001271782A1 (en) |
| WO (1) | WO2002003990A2 (en) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CO5271709A1 (en) * | 2000-01-12 | 2003-04-30 | Pfizer Prod Inc | COMPOSITIONS AND PROCEDURES FOR THE AND TREATMENT OF AFFECTIONS RESPONDING TO STROGENS |
| US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| MX2007011453A (en) * | 2005-04-22 | 2008-02-12 | Alantos Pharmaceuticals Holding Inc | Dipeptidyl peptidase-iv inhibitors. |
| US20070100893A1 (en) * | 2005-10-31 | 2007-05-03 | Sigmatel, Inc. | System and method for accessing data from a memory device |
| SMT202100433T1 (en) | 2015-10-01 | 2021-09-14 | Olema Pharmaceuticals Inc | Tetrahydro-1h-pyrido[3,4-b]indole anti-estrogenic drugs |
| RS63791B1 (en) | 2015-12-09 | 2022-12-30 | Univ Illinois | Benzothiophene-based selective estrogen receptor downregulators |
| CN109562107A (en) | 2016-05-10 | 2019-04-02 | C4医药公司 | Heterocycle degron body for target protein degradation |
| WO2017197051A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Amine-linked c3-glutarimide degronimers for target protein degradation |
| CN109641874A (en) | 2016-05-10 | 2019-04-16 | C4医药公司 | C for target protein degradation3The glutarimide degron body of carbon connection |
| CN120887906A (en) | 2016-05-10 | 2025-11-04 | C4医药公司 | Spirocyclic degradation determinant for target protein degradation |
| MX2019000200A (en) | 2016-07-01 | 2019-09-26 | G1 Therapeutics Inc | Pyrimidine-based antiproliferative agents. |
| WO2018081168A2 (en) | 2016-10-24 | 2018-05-03 | The Board Of Trustees Of The University Of Illinois | Benzothiophene-based selective mixed estrogen receptor downregulators |
| NZ754865A (en) | 2017-01-06 | 2023-07-28 | G1 Therapeutics Inc | Combination therapy for the treatment of cancer |
| TW201835064A (en) | 2017-02-10 | 2018-10-01 | 美商G1治療公司 | Benzothiophene estrogen receptor modulators |
| CN118440096A (en) | 2017-06-20 | 2024-08-06 | C4医药公司 | Degradation stator and degradation determinant for N/O-ligation of protein degradation |
| EA201992768A1 (en) | 2017-06-29 | 2020-05-19 | Г1 Терапьютикс, Инк. | MORPHOLOGICAL FORMS G1T38 AND METHODS FOR PRODUCING THEM |
| CN120698983A (en) | 2018-12-20 | 2025-09-26 | C4医药公司 | Targeted protein degradation |
| WO2021007146A1 (en) | 2019-07-07 | 2021-01-14 | Olema Pharmaceuticals, Inc. | Regimens of estrogen receptor antagonists |
| WO2021127561A1 (en) | 2019-12-20 | 2021-06-24 | C4 Therapeutics, Inc. | Isoindolinone and indazole compounds for the degradation of egfr |
| KR20220166797A (en) | 2020-03-05 | 2022-12-19 | 씨4 테라퓨틱스, 인코포레이티드 | Compounds for targeted degradation of BRD9 |
| IL300397A (en) | 2020-08-05 | 2023-04-01 | C4 Therapeutics Inc | Compounds for targeted degradation of ret |
| KR20240018446A (en) | 2021-06-08 | 2024-02-13 | 씨4 테라퓨틱스, 인코포레이티드 | Therapy for Degradation of Mutant BRAF |
| EP4565585A1 (en) | 2022-08-03 | 2025-06-11 | Bristol-Myers Squibb Company | Compounds for modulating ret protein |
| JP2025540906A (en) | 2022-11-04 | 2025-12-17 | ブリストル－マイヤーズ スクイブ カンパニー | RET-LDD protein inhibitor |
| KR20250117789A (en) | 2022-11-04 | 2025-08-05 | 브리스톨-마이어스 스큅 컴퍼니 | RET-LDD protein degrader |
| AU2024310341A1 (en) | 2023-06-30 | 2026-02-12 | Merck Patent Gmbh | Heterobifunctional compounds for the degradation of kras protein |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5677321A (en) | 1996-02-29 | 1997-10-14 | Synaptic Pharmaceutical Corporation | 5- and 6-(2-imidazolin-2-ylamino) and -(2-thiazolin-2-ylamino)-benzothiazoles as alpha-2 adrenergic ligands |
| US5880137A (en) | 1996-04-19 | 1999-03-09 | American Home Products Corporation | 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents |
| TW397821B (en) * | 1996-04-19 | 2000-07-11 | American Home Produits Corp | 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof |
| US5780497A (en) | 1996-04-19 | 1998-07-14 | American Home Products Corporation | 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents |
| ES2162198T3 (en) * | 1996-04-19 | 2001-12-16 | American Home Prod | STROGEN AGENTS. |
| DE69707509D1 (en) | 1996-07-12 | 2001-11-22 | Novo Nordisk As | 2-PHENYL-3-AZOYLBENZOTHIOPHENE TO REDUCE INTRAOCULAR PRESSURE |
| IL135343A0 (en) | 1997-10-15 | 2001-05-20 | American Home Prod | Novel aryloxy-alkyl-dialkylamines |
-
2001
- 2001-06-29 AU AU2001271782A patent/AU2001271782A1/en not_active Abandoned
- 2001-06-29 US US09/896,223 patent/US6509332B2/en not_active Expired - Fee Related
- 2001-06-29 WO PCT/US2001/021082 patent/WO2002003990A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002003990A2 (en) | 2002-01-17 |
| WO2002003990A3 (en) | 2002-09-12 |
| US20020019433A1 (en) | 2002-02-14 |
| US6509332B2 (en) | 2003-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2001271782A1 (en) | Use of substituted insole compounds for treating excessive intraocular pressure | |
| AU2001282873A1 (en) | Quinuclidine-substituted aryl compounds for treatment of disease | |
| AU2001284645A1 (en) | Quinuclidine-substituted aryl compounds for treatment of disease | |
| AU2002234017A1 (en) | Disposable shoe cover | |
| AU2001284646A1 (en) | Quinuclidine-substituted heteroaryl moieties for treatment of disease | |
| AU2001282875A1 (en) | Quinuclidine-substituted heteroaryl moieties for treatment of disease | |
| AU2002213308A1 (en) | Methods of selecting compounds for modulation of bladder function | |
| WO2001060347A3 (en) | Method for treating ocular pain | |
| AU2001233081A1 (en) | Composition for treatment of stress | |
| AU2001271706A1 (en) | Use of substituted indole compounds for treating breast disorders | |
| AU2001292480A1 (en) | Novel pyridazine compounds for the treatment of diabetes | |
| AU2000276362A1 (en) | Composition for the treatment of diabetes | |
| AU2002210385A1 (en) | Furazanyl-triazole derivates for the treatment of diseases | |
| AU2001253749A1 (en) | 2-fluorobenzenesulfonyl compounds for the treatment of inflammation | |
| AU2001296765A1 (en) | Use of n-halamine biocidal polymer for odor control | |
| AU2002322481A1 (en) | Use of r-nsaid compounds for anti-hiv treatment | |
| AU2002303145A1 (en) | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases | |
| GB0301137D0 (en) | Compounds for reducing intraocular pressure | |
| AU2003270683A1 (en) | Compounds for the treatment of premature ejaculation | |
| AU2002322551A1 (en) | Antisense modulation of rip2 expression | |
| AU2001234270A1 (en) | Bandage for orthopaedic use | |
| AU2000231423A1 (en) | Specific therapeutic composition for treating aids | |
| AU2001227117A1 (en) | Outsole for shoes | |
| AU2001256278A1 (en) | Use of cse inhibitors for treating heart failure | |
| AU2000263936A1 (en) | Substance p analogs for the treatment of cancer |